Med-Fine Capital is a Shanghai-based venture capital firm specializing in early-stage healthcare and life sciences investments across China. The firm focuses on biotech, medical devices, diagnostics, digital health, and healthcare services, managing both RMB and USD funds with a portfolio of over 60 companies.
33% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-a (40% of deals). Average disclosed round size is $41.5M (across 12 rounds with reported amounts).
Portfolio
8
Fund Size
—
Top Stage
Series A
Last 12 Mo
0
Team
Jack Zhou
Founder and Managing Partner
周玉建 (Yujian Zhou)
Managing Partner
Yang Bai
Partner and Managing Director
Vince Deng
Partner and Head of Biotech Investment
An Xiao
Healthcare investment professional
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 VelaVigo | Seed | $60M | Jul 2025 |
 Degron Therapeutics | Series A | $22M | Jun 2022 |
| LLynk Pharmaceuticals | Unknown | $50M | Aug 2021 |
 Lynk Pharmaceuticals | Series B | $50M | Aug 2021 |
| LLynk Pharmaceuticals | Series B | $50M | Jan 2021 |
| Lynk Pharmaceuticals | Series B | $50M | Jan 2021 |
 Alebund | Series B | $60M | Jan 2021 |
| LLynk Pharmaceuticals | Series A | $20M | Jan 2020 |
| Lynk Pharmaceuticals | Series A | $20M | Jan 2020 |
| Alebund | Series A | — | Jan 2020 |
| LLynk Pharmaceuticals | Seed | — | Jan 2018 |
| Lynk Pharmaceuticals | Seed | — | Jan 2018 |
| LLarkspur | Unknown | $35.5M | — |
 Allorion Therapeutics | Series A | $40M | — |
| AAllorion | Series A | $40M | — |
Top Co-Investors
Last updated: 20 October 2026